US equities |
MU $1,080.25 ▲+3.32% NVDA $237.16 ▼-0.87% SNDK $1,700.11 ▲+2.39% SPCX $167.73 ▼-2.44% AMD $642.08 ▼-1.13% TSLA $377.95 ▼-0.72% INTC $112.53 ▲+0.02% AAPL $337.00 ▲+1.01%
FinancialContent

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

21.97 +0.09 (+0.41%)
Delayed Quote Updated: 3:23 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
Boston Legacy FC Announces Sensory Room Sponsorship with Collegium Pharmaceutical
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Report Fourth Quarter and Full-Year 2025 Financial Results on February 26, 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) Presents a Classic Value Case with High Earnings and Low Valuation ↗
Via Chartmill
Collegium Pharmaceutical Inc (NASDAQ:COLL) Presents a Compelling Value Investment Case ↗
Via Chartmill
News headline image
1 Profitable Stock on Our Watchlist and 2 That Underwhelm
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my... 
Via StockStory
News headline image
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025 ↗
An executive vice president at a top pharmaceutical company sold shares towards the end of 2025, while the company's shares reached record numbers that year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
News headline image
Collegium Provides 2026 Financial Guidance and Business Update
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
3 Russell 2000 Stocks Walking a Fine Line
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
News headline image
Collegium Announces the Closing of $980 Million Syndicated Credit Facility
Five-Year Financing with Favorable Terms that Significantly Reduce Interest Rate 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
2 Reasons to Avoid COLL and 1 Stock to Buy Instead
Collegium Pharmaceutical has been on fire lately. In the past six months alone, the company’s stock price has rocketed 68.7%, setting a new 52-week high of $49.89 per share. This was partly thanks to... 
Via StockStory
Topics Supply Chain
News headline image
3 Cash-Producing Stocks We Think Twice About
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows Strong Earnings Momentum and Bullish Technical Setup ↗
Collegium Pharmaceutical (COLL) shows strong earnings growth and a bullish technical setup, offering a potential breakout opportunity for momentum investors. 
Via Chartmill
News headline image
3 Unpopular Stocks We Find Risky
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other... 
Via StockStory
News headline image
Collegium Pharmaceutical Inc (NASDAQ:COLL) Fits the Minervini Growth Momentum Strategy ↗
Collegium Pharmaceutical (COLL) aligns with Mark Minervini's SEPA strategy, showing a strong technical uptrend and robust fundamental earnings and sales growth. 
Via Chartmill
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Growth Stock Set to Flourishand 2 Facing Challenges
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
News headline image
1 Mooning Stock with Promising Prospects and 2 Facing Challenges
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
News headline image
1 Small-Cap Stock with Exciting Potential and 2 We Avoid
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q3 Earnings: Eli Lilly (NYSE:LLY) Best of the Bunch
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Eli Lilly (NYSE:LLY) and the... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium Pharmaceutical Inc (NASDAQ:COLL) Shows High Growth Momentum with Strong Technicals ↗
Discover how Collegium Pharmaceutical (COLL) combines a strong technical uptrend with powerful earnings growth, marking it as a high-potential stock. 
Via Chartmill
News headline image
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q3 Earnings Call
Collegium Pharmaceutical’s third quarter was marked by robust demand for its ADHD medication Jornay PM and continued resilience in its pain management portfolio. Management pointed to a successful... 
Via StockStory
Topics Earnings
News headline image
1 Safe-and-Steady Stock with Competitive Advantages and 2 We Brush Off
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
2 Momentum Stocks with Exciting Potential and 1 We Find Risky
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Topics Credit Cards
News headline image
COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 31.4% year on year to $209.4 million. The company’s full-year revenue... 
Via StockStory
News headline image
Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today
Shares of pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) jumped 11.6% in the morning session after the company reported strong third-quarter 2025 financial results, beating analyst... 
Via StockStory
Topics Economy Government World Trade
< Previous 1 2 3 4 5 6 7 8 9 10 Next >